Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab

Digestive and Liver Disease

Volumn 39, Issue 9, 2007, Pages 811-817

  Hassan, C ^a   Ierardi, E ^b   Burattini, O ^b   De Francesco, V ^b   Zullo, A ^a   Stoppino, G ^b   Panella, C ^b   Morini, S ^a  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Biologic therapy; Immunohistochemistry; Infliximab; TNF ; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL COUNT; CLINICAL ARTICLE; COLON BIOPSY; COLONOSCOPY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEUTROPHIL; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; REMISSION; ULCERATIVE COLITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547691199     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.06.003     Document Type: Article

References (29)

1. Reimund J.M., Wittersheim C., Dumont S., Muller C.D., Kenney J.S., Baumann R., et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 39 (1996) 684-689
2. Monteleone G., Monteleone I., Fina D., Vavassori P., Del Vecchio Blanco G., Caruso R., et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 128 (2005) 687-694
3. Fuss I.J., Neurath M., Boirivant M., Klein J.S., de la Motte C., Strong S.A., et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157 (1996) 1261-1270
4. Plevy S.E., Landers C.J., Prehn J., Carramanzana N.M., Deem R.L., Shealy D., et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 159 (1997) 6276-6282
5. Berner B., Akca D., Jung T., Muller G.A., and Reuss-Borst M.A. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol 27 (2000) 1128-1135
6. Murch S.H., Lamkin V.A., Savage M.O., Walker-Smith J.A., and MacDonald T.T. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32 (1991) 913-917
7. Murch S.H., Braegger C.P., Walker-Smith J.A., and MacDonald T.T. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 34 (1993) 1705-1709
8. Braegger C.P., Nicholls S., Murch S.H., Stephens S., and MacDonald T.T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339 (1992) 89-91
9. Knight D.M., Trinh H., Le J., Siegel S., Shealy D., McDonough M., et al. Construction and initial characterization of a mouse-human chimeric anti-TNF-antibody. Mol Immunol 30 (1993) 1443-1453
10. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
11. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
12. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulising Crohn's disease. N Engl J Med 350 (2004) 876-885
13. Baert F.J., D'Haens G.R., Peeters M., Hiele M.I., Schaible T.F., Shealy D., et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116 (1999) 22-28
14. Ulfgren A.K., Andersson U., Engstrom M., Klareskog L., Maini R.N., and Taylor P.C. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 43 (2000) 2391-2396
15. Schroeder K.W., Tremaine W.J., and Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med 317 (1987) 1625-1629
16. Morson B.C., and Dawson I.M.P. Gastro-intestinal Pathology. 2nd ed. (1979), Blackwell Scientific Publications pp. 530-3
17. Ierardi E., Monno R.A., Gentile A., Francavilla R., Burattini O., Marangi S., et al. Helicobacter Heilmannii gastritis: a histological and immunohistochemical trait. J Clin Pathol 54 (2001) 774-777
18. In: Sokal R.R., and Rohlf F.J. (Eds). Biometry (1969), W.H. Freeman, San Francisco
19. Seitz M., Wirthmuller U., Moller B., and Villiger P.M. The -308 tumour necrosis factor-{alpha} gene polymorphism predicts therapeutic response to TNF{alpha}-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 46 (2007) 93-96
20. Targan S.R., and Karp L.C. Defects in mucosal immunity leading to ulcerative colitis. Immunol Rev 206 (2005) 296-305
21. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., and Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986. J Immunol 175 (2005) 5-14
22. Schreiber S., Fedorak R.N., Nielsen O.H., Wild G., Williams C.N., Nikolaus S., et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119 (2000) 1461-1472
23. Hassan C., Zullo A., Ierardi E., Burattini O., De Francesco V., and Morini S. Tumour necrosis factor alpha downregulation and therapeutic response to infliximab in a case of segmental colitis associated with diverticula. Gut 55 (2006) 589-590
24. Lugering A., Schmidt M., Lugering N., Pauels H.G., Domschke W., and Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121 (2001) 1145-1157
25. ten Hove T., van Montfrans C., Peppelenbosch M.P., and van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50 (2002) 206-211
26. Westermann B., Engelhardt B., and Hoffmann J. Migration of T-cells in vivo: molecular mechanisms and clinical implications. Ann Intern Med 135 (2001) 279-295
27. Principi M., Day R., Marangi S., Burattini O., De Francesco V., Ingrosso M., et al. Differential immunohistochemical expression of syndecan-1 and tumor necrosis factor alpha in colonic mucosa of patients with Crohn's disease. Immunopharmacol Immunotoxicol 28 (2006) 185-195
28. Macias I., Garcia-Perez S., Ruiz-Tudela M., Medina F., Chozas N., and Giron-Gonzalez J.A. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis. J Rheumatol 32 (2005) 2102-2108
29. Mizoguchi E., Mizoguchi A., Takedatsu H., Cario E., de Jong Y.P., Ooi C.J., et al. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology 122 (2002) 134-144